CRISPR-Cas in Pseudomonas aeruginosa provides transient population-level immunity against high phage exposures
The ISME Journal · 08.01.2024 · 18 (1)
DOI: 10.1093/ismejo/wrad039 ↗Kurz gefasst
Fachartikel in der Zeitschrift The ISME Journal, online erschienen am 10.01.2024. Verfasst von Bridget N J Watson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences, University of Exeter, Penryn, Cornwall, TR10 9FE, United Kingdom. Hauptthemen laut MEDLINE: Bacteriophages. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Biotechnology and Biological Sciences Research Council, Wellcome Trust.
Abstract (Originalsprache)
The prokaryotic adaptive immune system, CRISPR-Cas (clustered regularly interspaced short palindromic repeats; CRISPR-associated), requires the acquisition of spacer sequences that target invading mobile genetic elements such as phages. Previous work has identified ecological variables that drive the evolution of CRISPR-based immunity of the model organism Pseudomonas aeruginosa PA14 against its phage DMS3vir, resulting in rapid phage extinction. However, it is unclear if and how stable such acquired immunity is within bacterial populations, and how this depends on the environment. Here, we examine the dynamics of CRISPR spacer acquisition and loss over a 30-day evolution experiment and identify conditions that tip the balance between long-term maintenance of immunity versus invasion of alternative resistance strategies that support phage persistence. Specifically, we find that both the initial phage dose and reinfection frequencies determine whether or not acquired CRISPR immunity is maintained in the long term, and whether or not phage can coexist with the bacteria. At the population genetics level, emergence and loss of CRISPR immunity are associated with high levels of spacer diversity that subsequently decline due to invasion of bacteria carrying pilus-associated mutations. Together, these results provide high resolution of the dynamics of CRISPR immunity acquisition and loss and demonstrate that the cumulative phage burden determines the effectiveness of CRISPR over ecologically relevant timeframes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biosciences, University of Exeter, Penryn, Cornwall, TR10 9FE, United Kingdom.
- Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, GA 30332, United States.
- Department of Microbiology and Immunology, University of Otago, Dunedin, 9059, Otago, New Zealand.
- Institute of Integrative Biology, University of Liverpool, Liverpool, Merseyside, L69 7BE, United Kingdom.
- Department of Biology, University of York, Wentworth Way, York, North Yorkshire YO10 3DB, United Kingdom.
Förderung
- European Research Council
- Biotechnology and Biological Sciences Research Council
- Wellcome Trust
- European Union’s Horizon 2020
- Natural Environment Research Council
- BBSRC
- Royal Society
- Leverhulme Trust
Zitieren
APA
Watson, B. N. J., Capria, L., Alseth, E. O., Pons, B. J., Biswas, A., Lenzi, L., Buckling, A., van Houte, S., Westra, E. R., & Meaden, S. (2024). CRISPR-Cas in Pseudomonas aeruginosa provides transient population-level immunity against high phage exposures. The ISME Journal, 18(1). https://doi.org/10.1093/ismejo/wrad039
Vancouver
Watson BNJ, Capria L, Alseth EO, Pons BJ, Biswas A, Lenzi L, et al. CRISPR-Cas in Pseudomonas aeruginosa provides transient population-level immunity against high phage exposures. The ISME Journal. 2024;18(1). doi:10.1093/ismejo/wrad039
BibTeX
@article{Watson2024,
author = {Watson, Bridget N J and Capria, Loris and Alseth, Ellinor O and Pons, Benoit J and Biswas, Ambarish and Lenzi, Luca and Buckling, Angus and van Houte, Stineke and Westra, Edze R and Meaden, Sean},
title = {CRISPR-Cas in Pseudomonas aeruginosa provides transient population-level immunity against high phage exposures},
journal = {The ISME Journal},
year = {2024},
volume = {18},
number = {1},
doi = {10.1093/ismejo/wrad039}
}
EUVIMED